Poor
Not Aligned
Patient Risk:
Medium
Summary
The AI response includes many statements about Kariva’s ingredients, contraceptive mechanism, dosing timing, missed-dose effects, and side effects that are not supported or contradicted by the provided FDA label excerpts. The only clearly label-aligned content pertains to the boxed warning theme of increased cardiovascular risk with oral contraceptives in the presence of smoking and underlying risk factors, and the provided contraindication/warning examples (history of blood clots/stroke, migraine patterns, uncontrolled hypertension, smoking-related risk factors).
Category Scores
Accurate Statements
Combined hormonal birth control can be unsafe for some people with certain conditions that increase the risk of blood clots or other serious complications.
Supported in concept by the provided WARNINGS boxed-warning theme: increased risks of serious conditions including thromboembolism/stroke, with risk increased by underlying risk factors (Section 5 boxed warning excerpt).
Kariva contraindications and warnings include a history of blood clots.
Consistent with contraindication language provided: thrombophlebitis/thromboembolic disorders and past history (Section 4 contraindications excerpt).
Kariva contraindications and warnings include a history of stroke.
Consistent with boxed warning listing stroke as a serious condition associated with oral contraceptives (Section 5 boxed warning excerpt); contraindication list includes cerebral vascular/coronary artery disease (Section 4 contraindications excerpt), though 'stroke' is not explicitly labeled in the excerpt as such.
Unsupported Statements
Kariva is a combined oral contraceptive pill.
The provided label excerpts do not include indication or formulation description; no support for 'combined oral contraceptive' in the supplied text.
Kariva contains levonorgestrel.
The supplied 'Drug/Active ingredients' section in the prompt differs (lists desogestrel and ethinyl estradiol), and the FDA excerpts provided do not confirm levonorgestrel.
Kariva prevents pregnancy mainly by stopping ovulation.
No mechanism-of-action statements are included in the provided label excerpts.
Kariva prevents pregnancy by thickening cervical mucus.
No mechanism-of-action statements are included in the provided label excerpts.
Thickened cervical mucus makes it harder for sperm to reach an egg.
No mechanism-of-action statements are included in the provided label excerpts.
Kariva is taken by mouth on a daily schedule.
No dosage/administration instructions are included in the provided label excerpts.
Combined oral contraceptive pills follow a repeating cycle that includes active hormone pills and a break week or reminder week with lower/no hormones.
No regimen/cycle structure is included in the provided label excerpts.
Starting Kariva at the right time in the menstrual cycle can provide contraception immediately.
No initiation timing guidance is included in the provided label excerpts.
Starting Kariva later usually requires backup contraception.
No initiation timing/backup contraception guidance is included in the provided label excerpts.
Backup contraception is commonly required for the first 7 days when starting later.
No initiation timing/backup contraception duration is included in the provided label excerpts.
Effectiveness depends on when Kariva is started relative to the menstrual cycle.
No initiation-timing effectiveness statements are included in the provided label excerpts.
If pills are missed, the risk of pregnancy increases.
No missed-dose/pregnancy risk statements are included in the provided label excerpts.
Missed-dose guidance for combined pills depends on how many pills were missed.
No missed-dose guidance is included in the provided label excerpts.
Missed-dose guidance for combined pills depends on whether missed pills were in the early or later part of the active pill cycle.
No missed-dose guidance is included in the provided label excerpts.
Common side effects of combined oral contraceptives include nausea.
No adverse reaction/side effect list is included in the provided label excerpts.
Common side effects of combined oral contraceptives include breast tenderness.
No adverse reaction/side effect list is included in the provided label excerpts.
Common side effects of combined oral contraceptives include headache.
No adverse reaction/side effect list is included in the provided label excerpts.
Common side effects of combined oral contraceptives include breakthrough bleeding (spotting).
No adverse reaction/side effect list is included in the provided label excerpts.
Common side effects of combined oral contraceptives include mood changes.
No adverse reaction/side effect list is included in the provided label excerpts.
Kariva contraindications and warnings include certain migraine patterns.
The provided contraindication excerpt does not mention migraine patterns; the AI statement is not supported by provided text.
Kariva contraindications and warnings include uncontrolled high blood pressure.
The provided contraindication excerpt does not include hypertension; only risk-factor language exists in the boxed warning excerpt.
Kariva contraindications and warnings include some smoking-related risk factors depending on age.
The provided warning excerpt discusses smoking and age-related risk (mid-thirties/older; over age 35/40) but does not specify an age-dependent contraindication list.
Combined pills carry a risk of blood clots.
The provided excerpts mention thromboembolism/stroke as serious conditions associated with oral contraceptives; however 'blood clots' as a generic statement is not directly stated in the provided text.
Combined pills carry a risk of deep vein thrombosis.
The provided excerpts do not explicitly mention 'deep vein thrombosis' in the warnings text provided (contraindications excerpt references past history of deep vein thrombophlebitis/thromboembolic disorders).
Combined pills carry a risk of pulmonary embolism.
The provided excerpts do not explicitly mention pulmonary embolism.
Seek urgent care if symptoms could indicate a clot, including sudden shortness of breath.
No patient instruction/urgent-care guidance is included in the provided label excerpts.
Seek urgent care if symptoms could indicate a clot, including chest pain.
No patient instruction/urgent-care guidance is included in the provided label excerpts.
Seek urgent care if symptoms could indicate a clot, including coughing blood.
No patient instruction/urgent-care guidance is included in the provided label excerpts.
Seek urgent care if symptoms could indicate a clot, including severe leg pain or swelling.
No patient instruction/urgent-care guidance is included in the provided label excerpts.
Seek urgent care if symptoms could indicate a clot, including sudden neurologic symptoms such as weakness.
No patient instruction/urgent-care guidance is included in the provided label excerpts.
Seek urgent care if symptoms could indicate a clot, including sudden neurologic symptoms such as trouble speaking.
No patient instruction/urgent-care guidance is included in the provided label excerpts.
Seek urgent care if symptoms could indicate a clot, including severe sudden headache.
No patient instruction/urgent-care guidance is included in the provided label excerpts.
Contradictions
High
AI Statement
Kariva contains levonorgestrel.
Label Reference
Drug/active ingredient description supplied in prompt states: 'Kariva® (desogestrel/ethinyl estradiol and ethinyl estradiol tablets USP)' (not levonorgestrel). No provided FDA excerpts support levonorgestrel.
Important Omissions
Accurate Kariva-specific active ingredients matching the provided product description (desogestrel/ethinyl estradiol) rather than levonorgestrel.
Importance:
High
Label-supported contraindication details beyond the limited excerpt (the response asserts multiple contraindication categories such as migraine patterns and uncontrolled hypertension without label evidence from the provided text).
Importance:
Moderate
Any label-supported dosing/starting/backup contraception and missed-pill guidance for Kariva.
Importance:
Moderate
Any label-supported adverse reaction listing for Kariva.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Several statements are unsupported by the provided label excerpts (mechanism, dosing/starting/backup, missed-dose guidance, side effects, and urgent-care instructions). The ingredient claim 'levonorgestrel' is directly inconsistent with the supplied Kariva product description. While the general cardiovascular risk theme aligns with the warnings excerpt, the lack of label support for many actionable details increases risk of misinformation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Major portion of claims (mechanism, dosing/starting/backup, missed-dose guidance, adverse effects, and urgent-care instructions) are not supported by the provided FDA label excerpts; ingredient claim conflicts with the provided active-ingredient description.
Suggested Improvement
Limit statements strictly to FDA label content provided (Section 5 boxed warnings about increased serious risks and Section 5.1/5.1.b smoking/age cardiovascular risk; Section 4 contraindication categories from the excerpt). Remove unsupported mechanism-of-action, regimen, missed-dose, side-effect frequency, and symptom/urgent-care instructions unless corresponding label text is provided.